Which hip care claims deserve a second look?

Does hip bursitis mean the small cushion is swollen?

Not always. Hip bursitis is a common name for soreness near the hip's outer bony point. A bursa is a small, soft pouch that keeps nearby parts from rubbing. The tendons beside it can be the main sore part. Lying on that side often makes the ache worse. Groin soreness from the joint feels different. One scan or one tender spot can't settle the cause alone. Ask, “Does my exam point to the joint, the outer tendons, or my back?”

What hurts matters more than the old label.

How do I judge a cash-pay treatment claim?

Have the clinic name the improvement you might feel and the likely wait. Get one price that includes each planned return visit. QC Kinetix calls its blood-based, non-surgical clinic procedures natural pain treatments. Clinics shorten platelet-rich plasma to PRP. To make it, staff take some blood, divide it in a spinning machine, and keep a layer rich in platelets. Platelets help bleeding stop when you're cut. A medical provider puts that layer at the sore joint or outer tendon. Ask if a doctor handles that step and what training the provider has. The clinic may call one form concentrated PRP. Ask how it's different and whether you'll pay more for it. Results aren't certain, and joint soreness may respond differently from a sore outer tendon.

Don't pay until the possible benefit, limits, and full cost make sense.

Does an X-ray decide whether I need surgery?

An X-ray can show joint wear, but it can't measure how much you hurt. Some people with marked wear still manage their daily tasks. Others hurt badly when the X-ray shows less wear. Your walking, sleep, stiffness, and hip movement matter too. Ask the person examining you what would make surgery worth discussing now. Then ask what may happen if you wait. You'll want both answers before choosing care that costs money and takes recovery time.

The X-ray and your daily trouble both matter.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programmes, tai chi, cane use and oral NSAIDs across hand, hip and knee OA - but its strong recommendations for topical NSAIDs and for intra-articular glucocorticoid injection are specific to the KNEE, not the hip.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.

   Hall M, et al. — Exercise for osteoarthritis of the hip.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD007912.pub3.

3. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

4. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

5. In a multicentre, randomized, placebo-controlled trial (n=85) of a single fluoroscopically-guided intra-articular hyaluronic acid injection for hip OA, the decrease in pain at 3 months did not differ from placebo (7.8 mm vs 9.1 mm on a 100 mm VAS; P=0.98), and responder rates were 33.3% versus 32.6%.

   Richette P, et al. — Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial.. Arthritis & Rheumatism, 2009. DOI: 10.1002/art.24301.

6. A systematic review and meta-analysis of six Level I/II randomized trials (211 PRP and 197 hyaluronic acid patients, mean follow-up ~12 months) found NO significant difference between PRP and hyaluronic acid in WOMAC, VAS or Harris Hip Score improvement for hip osteoarthritis, including in the leukocyte-poor PRP subanalysis.

   Belk JW, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials.. Arthroscopy, 2022. DOI: 10.1016/j.arthro.2021.11.005.

7. In 45 volunteers with no history of hip pain, symptoms, injury or surgery, blinded 3.0-T MRI found abnormalities in 73% of hips - labral tears in 69%, chondral defects in 24%, subchondral cysts in 16% and osseous bumps in 20%. A labral tear on MRI is therefore not by itself an explanation for hip pain.

   Register B, et al. — Prevalence of abnormal hip findings in asymptomatic participants: a prospective, blinded study.. American Journal of Sports Medicine, 2012. DOI: 10.1177/0363546512462124.

8. In a placebo-controlled, participant- and assessor-blinded RCT of 102 people with radiographically confirmed hip OA, 12 weeks of active physical therapy (education, manual therapy, home exercise, gait aid) did NOT beat sham ultrasound and inert gel on pain (mean difference 6.9 mm favouring sham, 95% CI -3.9 to 17.7) or function at week 13, and mild adverse effects were more common in the active group (41% vs 14%).

   Bennell KL, et al. — Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial.. JAMA, 2014. DOI: 10.1001/jama.2014.4591.

9. In January 2025 federal court orders permanently banned the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injection treatments for conditions including osteoarthritis and joint pain.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments, Ordered to Pay More than $5.1 Million.. FTC, 2025.

10. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax regulation - and concluded that regulators must better oversee this marketplace.

    Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

11. A 2025 review of mesenchymal stem cell injection research in orthopaedics identified 449 registered clinical trials, of which only 159 (35.4%) were complete and only 56 (12.5%) had published results in peer-reviewed journals. Hip and knee osteoarthritis were the most common indications (37.6%). Reported cell concentrations spanned three orders of magnitude and 55.5% of protocols did not specify a concentration at all.

    Bezuglov E, et al. — Mesenchymal stem cells injections in traumatology and orthopaedics: common practice or still a promising area with many uncertainties?. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-09123-8.

12. In a cohort of 2953 hips followed 11-28 years, radiographic hip OA raised the hazard of total hip replacement 13-fold (HR 13.2, 95% CI 8.1-21) - but more than four in five hips with radiographic hip OA had still NOT had a replacement 11-28 years later.

    Franklin J, et al. — Natural history of radiographic hip osteoarthritis: A retrospective cohort study with 11-28 years of followup.. Arthritis Care & Research, 2011. DOI: 10.1002/acr.20412.

13. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

    American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.

14. OARSI 2019 designates arthritis education plus structured land-based exercise as CORE treatments for hip OA, and explicitly states that intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise - Level 1B/2 treatments for KNEE OA - were NOT recommended for individuals with hip or polyarticular OA. Oral and transdermal opioids are strongly not recommended (Level 5).

    Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.